FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.-Reference-Cited by-同舟云学术

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:3512-3512
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ychou Marc¹,Rivoire Michel²,Thezenas Simon³,Guimbaud Rosine⁴,Ghiringhelli Francois⁵,Mercier-Blas Anne⁶,Mineur Laurent⁷,Francois Eric⁸,Khemissa Faiza⁹,Moussata Driffa¹⁰,Becouarn Yves¹¹,Houyau Philippe¹²,Aparicio Thomas¹³,Adam Rene¹⁴,Galais Marie-Pierre¹⁵,Audemar Franck¹⁶,Assenat Eric¹⁷,Stanbury Trevor¹⁸,Bouche Olivier¹⁹

Affiliation:

1. Montpellier Cancer Institute, Montpellier, France;

2. Centre Léon Bérard, Lyon, France;

3. Institut Régional du Cancer Montpellier, Montpellier, France;

4. University Hospital of Rangueil, Toulouse, France;

5. Centre Georges-François Leclerc, Dijon, France;

6. Centre Hospitalier Privé de Saint-Grégoire, Saint-Grégoire, France;

7. Radiotherapy and Oncology GI and Liver Unit, Institut Sainte-Catherine, Avignon, France;

8. Department of Medical Oncology, Centre Antoine-Lacassagne, Nice, France;

9. CH Saint Jean, Perpignan, France;

10. CHU Tours, TOURS, France;

11. Institut Bergonié, Bordeaux, France;